Research
Tracing the HIV-1 subtype B mobility in Europe: a phylogeographic approach
-
* Corresponding author: Dimitrios Paraskevis dparask@cc.uoa.gr
1 Katholieke Universiteit Leuven, Rega Institute for Medical research, Minderbroederstraat 10, B-3000 Leuven, Belgium
2 National Retrovirus Reference Center, Department of Hygiene Epidemiology and Medical Statistics, Medical School, University of Athens, M. Asias 75, GR-11527, Athens, Greece
3 Department of Zoology, University of Oxford, South Parks Road, Oxford, OX1 3PS, UK
4 University Medical Center Utrecht, Department of Virology, G04.614, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
5 Department of Virology, Erasmus MC, University Medical Centre, Postbus 2040 3000 CA Rotterdam, the Netherlands
6 Department of Microbiology, Tumor and Cellbiology, Karolinska Institutet, SE 171 77 Stockholm, Sweden
7 Dept of Virology, Swedish Institute for Infectious Disease Control, SE-171 82 Solna, Sweden
8 University of Foggia, Clinic of Infectious Diseases, Ospedali Riuniti – Via L. Pinto 71100 Foggia, Italy
9 Center for Research in Virology, University of Bergen, Bergen High Technology Center, N-5020 Bergen, Norway
10 University of Milano, Institute of Infectious and Tropical Diseases, Via Festa del Perdono 7, 20122 Milano, Italy
11 Diagnostica and Ricerca San Raffaele, Centro San Luigi, I.R.C.C.S. Istituto Scientifico San Raffaele, Milan, Italy
12 Universidade Nova de Lisboa, Laboratorio de Virologia, Rua da Junqueira 96 1349-008 Lisboa, Portugal
13 EA 3620, Universite Paris Descartes, Virologie, CHU Necker, Paris France
14 National Virus Reference Laboratory, University College, Dublin, Ireland
15 INSERM U263 et SC4, Faculté de médecine Saint-Antoine, Université Pierre et Marie Curie, 27 rue de Chaligny, F-75571 Paris, France
16 Department of Infectious Diseases, Catholic University, L.go A. Gemelli, 8 00168 Rome, Italy
17 Hospital Carlos III, Hospital Carlos III, Madrid, Spain
18 Internal Medicine, UZ Leuven, Belgium
19 National. HIV Reference Lab, Central Virology, Public Health Laboratories, MOH Central Virology, Sheba Medical Center, 2 Ben-Tabai Street, Israel
20 Robert Koch Institut (RKI), Nordufer 20, 13353 Berlin, Germany
21 University Medical Center Utrecht, Department of Internal Medicine and Infectious Diseases F02.126, Heidelberglaan 100, 3584 CX, Utrecht, the Netherlands
22 Hospital for Infectious Diseases, Center for Diagnosis & Therapy Warsaw 37, Wolska Str. 01-201 Warszawa, Poland
23 University of Erlangen, Schlossplatz 4, D-91054 Erlangen, Germany
24 ICVC Charity Laboratories, 3d floor, Apollo Centre Desborough Road High Wycombe, Buckinghamshire, HP11 2QW, UK
25 Inserm, U822, Le Kremlin-Bicêtre, F-94276, France
26 Statens Serum Institut Copenhagen, Retrovirus Laboratory, department of virology, building 87, Division of Diagnostic Microbiology 5, Artillerivej 2300 Copenhagen, Denmark
27 Centre for Infectious Disease Control (Epidemiology & Surveillance), National Institute for Public Health and the Environment (RIVM), 3720 BA Bilthoven, the Netherlands
28 Ullevaal University Hospital, Department of Infectious Diseases Kirkeveien 166, N-0407 Oslo, Norway
29 Laboratory of Virology, Geneva University Hospital and University of Geneva Medical School, Geneva, Switzerland
30 Institute of Virology, Medical University Vienna, Kinderspitalgasse 15, Vienna, Austria
31 IrsiCaixa Foundation, Hospital Germans Trias i Pujol, Ctra. de Canyet s/n, 08916 Badalona (Barcelona), Spain
32 National Public Health Institute, HIV laboratory and department of infectious disease epidemiology, Mannerheimintie 166, FIN-00300 Helsinki, Finland
33 Centre Hospitalier de Luxembourg, Retrovirology Laboratory, National service of Infectious Diseases, 4 Rue Barblé, L-1210, Luxembourg
34 University of Belgrade School of Medicine, Institute of Microbiology and Immunology Virology Department, Dr Subotica 1, 11000 Belgrade, Serbia
35 Section of Microbiology, Department of Molecular Biology, University of Siena, Italy
Retrovirology 2009, 6:49 doi:10.1186/1742-4690-6-49
Published: 20 May 2009Additional files
Additional file 1:
Tables S1 and S2. Table S1 – Number of calculated migration events (medians) between countries. Table S2 – Differences of the medians between observed and the expected migration events. Cells in bold and underlined bold denote significantly higher and lower migration numbers, respectively.
Format: DOC Size: 164KB Download file
This file can be viewed with: Microsoft Word Viewer
Additional file 2:
Figure S1 (part A). Significant HIV exporting (A and B) and importing (C and D) migration events between different countries as estimated by statistical phylogeography study For all countries, 90 sequences were included per analysis, except for Belgium (BEL), Greece (GRC) and the Netherlands (NLD) for which 86, 73 and 84 sequences were included. For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences were available, respectively. This lower number of sequences explains why the significantly high migration count for these countries is lower than for the other countries. Country code as in table 1.
Format: GIF Size: 49KB Download file
Additional file 3:
Figure S1 (part B). Significant HIV exporting (A and B) and importing (C and D) migration events between different countries as estimated by statistical phylogeography study For all countries, 90 sequences were included per analysis, except for Belgium (BEL), Greece (GRC) and the Netherlands (NLD) for which 86, 73 and 84 sequences were included. For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences were available, respectively. This lower number of sequences explains why the significantly high migration count for these countries is lower than for the other countries. Country code as in table 1.
Format: GIF Size: 45KB Download file
Additional file 4:
Figure S1 (part C). Significant HIV exporting (A and B) and importing (C and D) migration events between different countries as estimated by statistical phylogeography study For all countries, 90 sequences were included per analysis, except for Belgium (BEL), Greece (GRC) and the Netherlands (NLD) for which 86, 73 and 84 sequences were included. For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences were available, respectively. This lower number of sequences explains why the significantly high migration count for these countries is lower than for the other countries. Country code as in table 1.
Format: GIF Size: 36KB Download file
Additional file 5:
Figure S1 (part D). Significant HIV exporting (A and B) and importing (C and D) migration events between different countries as estimated by statistical phylogeography study For all countries, 90 sequences were included per analysis, except for Belgium (BEL), Greece (GRC) and the Netherlands (NLD) for which 86, 73 and 84 sequences were included. For Israel (ISR), Norway (NOR) and Serbia (YUG) <<< 90 sequences were available, respectively. This lower number of sequences explains why the significantly high migration count for these countries is lower than for the other countries. Country code as in table 1.
Format: GIF Size: 33KB Download file
